Compare Gitlab Inc (GTLB) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Eli Lilly And Co — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 116.6× Gitlab Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Eli Lilly And Co for 93 Days on average.
| GTLB | LLY | |
|---|---|---|
Market Cap | $8.92B | $1.04T |
Volume | 4,716,893 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $53.56 | $1.28K |
52-Week Low | $19.42 | $799.57 |
Typical Hold Time | 62 Days | 93 Days |
Enterprise Value | $7.66B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% today and near its 52-week high, with strong technical momentum indicated by moving averages. The company shows impressive revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net income margin of -4.99%. Recent Q2 2026 earnings beat expectations, and the stock surged on raised guidance and AI-driven demand optimism.
Outlook: GitLab benefits from AI integration in software development and strong sales momentum, but high valuation multiples (P/E 521) and persistent losses pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution challenges and competitive pressures.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
